Thanks.....I appreciate the information in your post concerning recent developments toward entering the HIV TAT market.
Your closing thoughts...........
"The most interesting point I have to make is this: If they choose the right phytocannabinoids for preclinical testing, and the results concerning safety profile and other factors are positive, this very same preclinical research can be used as an argument and as evidence to support their submissions to the FDA of other medicines based on these phytocannabinoids. Hence everything is connected and the HIV avenue represents not only progress in this particular avenue, but in all phytocannabinoid-based medical avenues CBIS is pursuing. This HIV avenue simply represents an opportunity for less resistance and more collaboration in getting phytocannabinoid-based medicine accepted as safe and effective."
I wish to point out CBIS has had longstanding participation in this avenue of research. They are not chasing a trend.....they are one of its leaders.....for.....many years.....Perhaps, someone can give us a time-frame snapshot of Dr. Melamede's participation in the struggle to treat the AIDS epidemic? I imagine he first picked up the thread of this cause way back.....when the problem first emerged.....?.....his dedication to.....caring for people.....with compassion.....is evident to me.....Public opinion.....is evaluating.....and debating the nature of the MMJ protocol.....
I had noticed Dr. Melamede participates in a broad spectrum of AIDS related research, and action groups.....A nice history for the CEO of CBIS to have in light of recent developments.
Best Wishes
AI
